ESALF News and Press, Eisai Co Ltd From 06/22/23

Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City TOKYO, June 22, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NO...

FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., June 12, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Admi...

Eisai Files Marketing Authorization Application for Lecanemab as Treatment For Early Alzheimer's Disease in South Korea TOKYO and CAMBRIDGE, Mass., June 8, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced today that Eisai has submitted a marketing aut...

Eisai to Present Latest Data on Lemborexant at the 37th Annual Sleep 2023 Meeting TOKYO, June 2, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced a total of eight poster presentations, including the latest data on its in-house discovered orexin receptor antagonist lemborexant (prod...

2023-06-01 12:09:13 ET Catalyst Pharmaceuticals ( NASDAQ: CPRX ) reaffirmed its full-year 2023 total revenue and products outlook. The company continues to expect FY23 revenue to be between $375M and $385M, growing 75% to 80% Y/Y (consensus $381.28M). Catalyst also reaffirme...

LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma TOKYO, May 26, 2023 - (JCN Newswire) - Eisai and Merck & Co., Inc., Rahway, NJ, USA (known...

2023-05-21 12:00:17 ET Developers have increasingly relied on an FDA shortcut to win accelerated drug approvals while their confirmatory trials got delayed at the expense of billions to the government-backed healthcare system, a recent analysis from Bloomberg News indicates. The...

2023-05-18 11:30:11 ET Cognition Therapeutics ( NASDAQ: CGTX ) stock rose ~9% on Thursday after the company said data for CT1812 was published in the journal Translational Neurodegeneration . The manuscript is titled, 'A Phase 1b Randomized Clinical Trial of CT1812 ...

2023-05-17 12:13:55 ET Alzheimer's drug developer Prothena Corporation ( NASDAQ: PRTA ) announced Tuesday that Billy Dunn, who previously led the FDA's Office of Neuroscience, is joining the company's board of directors. The appointment comes less than three months after the FDA...

2023-05-15 12:35:17 ET Eisai press release ( OTCPK:ESALF ): FY GAAP EPS of ¥193.31. Revenue of ¥744.4B (-1.6% Y/Y). For further details see: Eisai GAAP EPS of ¥193.31, revenue of ¥744.4B